Literature DB >> 6358356

On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.

P Parham.   

Abstract

Methods for the production and purification of F(ab')2 fragments from BALB/c monoclonal IgG1, IgG2a, and IgG2b with pepsin and other proteases were examined. The overall susceptibility to degradation is IgG2b greater than IgG2a greater than IgG1. Stable F(ab')2 can be produced in good yield from IgG1 with pepsin at pH 3.5 to 4.0 and can be made directly by pepsin treatment of ascites fluids or cell culture supernatants containing IgG1. IgG2a is cleaved in two steps by pepsin, first to F(ab')2 and then to Fab'. With carefully chosen conditions, F(ab')2 can be obtained in acceptable yield. The primary cleavage for the IgG2a heavy chain appears to be on the COOH terminal side of the interheavy chain disulfides, and secondary cleavage is on the NH2-terminal side. For IgG2b the reverse is true, and F(ab')2 has not been obtained in useful amounts; however, the primary cleavage of IgG2b appears to be assymetric with respect to the two heavy chains, and Fab/c fragments that have one Fab plus Fc can be made. Digestion with elastase resulted in the best yield of Fab/c. This finding may provide a method for retaining cytotoxicity in monoclonal antibodies against cell surface antigens while eliminating their capacity to modulate. The cleavage patterns of the three classes of IgG are rationalized in terms of the structure of their hinge regions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6358356

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  88 in total

1.  Preparation and purification of F(ab')(2) fragment from anti hepatoma mouse IgG(1) mAb.

Authors:  Cheng-Gang Liu; Mei-Cai Zhu; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

Review 2.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Studies of a monoclonal antibody to skeletal keratan sulphate. Importance of antibody valency.

Authors:  A R Poole; C Webber; A Reiner; P J Roughley
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

4.  The binding parameters of radiolabelled monoclonal F (ab')2 and Fab' fragments relative to immunoglobulin G in reactions with surface-bound antigens.

Authors:  J G Fjeld; T E Michaelsen; K Nustad
Journal:  Eur J Nucl Med       Date:  1992

5.  Optimization of Enzymatic Antibody Fragmentation for Yield, Efficiency, and Binding Affinity.

Authors:  Andrew W L Kinman; Rebecca R Pompano
Journal:  Bioconjug Chem       Date:  2019-01-28       Impact factor: 4.774

6.  Further characterization of immunomodulation by a monoclonal antibody against Streptococcus mutans antigen P1.

Authors:  Nikki R Rhodin; Marloes L J A Van Tilburg; Monika W Oli; William P McArthur; L Jeannine Brady
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Increased expression of long pentraxin PTX3 in inflammatory bowel diseases.

Authors:  Shingo Kato; Mitsuko Ochiai; Tomoya Sakurada; Shino Ohno; Kyoko Miyamoto; Mina Sagara; Masataka Ito; Kyoko Takeuchi; Junko Imaki; Kazuro Itoh; Koji Yakabi
Journal:  Dig Dis Sci       Date:  2007-11-08       Impact factor: 3.199

8.  Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.

Authors:  U D Staerz; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

9.  CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4.

Authors:  N Thieblemont; N Haeffner-Cavaillon; A Ledur; J L'Age-Stehr; H W Ziegler-Heitbrock; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

10.  Bovine rotavirus type detection by neutralizing monoclonal antibodies.

Authors:  E Cornaglia; Y Elazhary; B Talbot
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.